Literature DB >> 18849660

Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications.

Baldomero M Olivera1, Maryka Quik, Michelle Vincler, J Michael McIntosh.   

Abstract

Conus peptides that are selectively targeted to different molecular isoforms of nicotinic acetylcholine receptors (nAChRs) have been identified and characterized; several have recently been shown to have significant biomedical potential. An emerging strategy for the discovery from animal biodiversity of subtype-specific ligands for ion channel families is described in this review. Characterization of the gene family encoding a set of related ligands is required for discovery using a molecular genetics approach; when discovery is guided by a knowledge of the phylogeny of the biodiverse animal lineage being used as a source of ligands, a rational, efficient scan of the library of putative ligands becomes feasible. Together, these constitute an approach to uncover subtype-specific ligands, called "concerted discovery"; this was applied to the alpha-conotoxins, a family of Conus peptides generally targeted to nAChRs. Subtype-specific alpha-conotoxins were developed that target two groups of nAChRs, alpha(6)* and alpha(9)*. alpha-conotoxin MII has become the defining ligand for identifying the alpha(6)* nAChR subtype. A synthetic analog, MII [E11A], further subdivides alpha(6)* nAChRs into those that contain an alpha(4) subunit and those that do not. Importantly, these two subtypes are differentially affected by nigrostriatal damage, findings of likely relevance to the pathopysiology of Parkinson's disease. In contrast, alpha-conotoxins that target alpha(9) nAChR subtypes have potential as analgesics for the treatment of neuropathic pain that develops after nerve injury. The discovery of alpha-conotoxin RgIA enabled the identification of a novel role for alpha(9)* nAChRs. Use of alpha(9)* nAChR antagonists is associated with reversal of inflammation caused by the nerve injury. Thus, subtype-specific alpha-conotoxins targeted to particular nAChR isoforms are not only useful for understanding the physiological role of these receptors, but can have important diagnostic and therapeutic applications as well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849660     DOI: 10.4161/chan.2.2.6276

Source DB:  PubMed          Journal:  Channels (Austin)        ISSN: 1933-6950            Impact factor:   2.581


  35 in total

1.  Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.

Authors:  Layla Azam; J Michael McIntosh
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

2.  Microhabitats within venomous cone snails contain diverse actinobacteria.

Authors:  Olivier Peraud; Jason S Biggs; Ronald W Hughen; Alan R Light; Gisela P Concepcion; Baldomero M Olivera; Eric W Schmidt
Journal:  Appl Environ Microbiol       Date:  2009-09-11       Impact factor: 4.792

3.  MmTX1 and MmTX2 from coral snake venom potently modulate GABAA receptor activity.

Authors:  Jean-Pierre Rosso; Jürgen R Schwarz; Marcelo Diaz-Bustamante; Brigitte Céard; José M Gutiérrez; Matthias Kneussel; Olaf Pongs; Frank Bosmans; Pierre E Bougis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 4.  Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

Authors:  Sharon R Letchworth; Paul Whiteaker
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

5.  Characterization of conantokin Rl-A: molecular phylogeny as structure/function study.

Authors:  Konkallu H Gowd; Maren Watkins; Vernon D Twede; Grzegorz W Bulaj; Baldomero M Olivera
Journal:  J Pept Sci       Date:  2010-08       Impact factor: 1.905

6.  In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.

Authors:  F Ivy Carroll; Hernán A Navarro; S Wayne Mascarella; Ana H Castro; Charles W Luetje; Charles R Wageman; Michael J Marks; Asti Jackson; M Imad Damaj
Journal:  ACS Chem Neurosci       Date:  2015-04-30       Impact factor: 4.418

7.  Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at the alpha9alpha10 nicotinic acetylcholine receptor.

Authors:  Reena Halai; Richard J Clark; Simon T Nevin; Jonas E Jensen; David J Adams; David J Craik
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

Review 8.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

9.  Functional expression of α7-nicotinic acetylcholine receptors by muscle afferent neurons.

Authors:  James C Baxter; Renuka Ramachandra; Dustin R Mayne; Keith S Elmslie
Journal:  J Neurophysiol       Date:  2014-06-25       Impact factor: 2.714

Review 10.  From foe to friend: using animal toxins to investigate ion channel function.

Authors:  Jeet Kalia; Mirela Milescu; Juan Salvatierra; Jordan Wagner; Julie K Klint; Glenn F King; Baldomero M Olivera; Frank Bosmans
Journal:  J Mol Biol       Date:  2014-08-01       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.